A fast determination of globotriaosylsphingosine in plasma for screening fabry disease using UPLC-ESI-MS/MS

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Globotriaosylsphingosine (lyso-Gb3) is considered as one of the biological marker for Fabry disease. To date, a reliable biomarker that reflects disease severity and progression has not been discovered to guide the management of Fabry disease. A new method included a simple protein precipitation with acetonitrile in 100 μL of plasma following analyte separation on an Phenomenex Kintex- C18 column using a gradient elution (0.1% formic acid in 5-90% acetonitrile). Total run time was within 12 min including sample preparation and MS/MS analysis. The limit of detection and limit of quantitation were 1 ng/mL and 2 ng/mL, respectively. The calibration curve was linear over the concentration range of 2.0-200.0 ng/mL (r2 = 0.9999). Inter-day accuracy and precision at 7 level were 93.4-100.7% with RSD of 0.55-5.97%. Absolute recovery was 97.6-98.6%. The method was applied to human and mice plasma, proved the suitability for quantification of lyso-Gb3 for screening, diagnosis and therapeutic monitoring of Fabry disease patients.

Cite

CITATION STYLE

APA

Yoon, H. R. (2015). A fast determination of globotriaosylsphingosine in plasma for screening fabry disease using UPLC-ESI-MS/MS. Mass Spectrometry Letters, 6(4), 116–119. https://doi.org/10.5478/MSL.2015.6.4.116

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free